Your company account is blocked and you cannot place orders. If you have questions, please contact your company administrator.

Lampalizumab (anti-Complement Factor D) - Primary antibody, specific to CFD, >95%, high purity, Human IgG1, Antibody of complement factor D

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Features and benefitsView More
  • Host species: Human
  • Species reactivity(Reacts with): Cynomolgus monkey,Human,Rabbit
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
Item Number
Ab175571
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175571-100μg
100μg
In stock
$109.90
Ab175571-1mg
1mg
In stock
$519.90
Ab175571-5mg
5mg
In stock
$1,399.90
Ab175571-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,239.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product NameLampalizumab (anti-Complement Factor D) - Primary antibody, specific to CFD, >95%, high purity, Human IgG1
SynonymsAdipsin antibody | Adipsin/complement factor D antibody | Adn antibody | C3 convertase activator antibody | CFAD_HUMAN antibody | CFD antibody | Complement factor D antibody | complement factor D preproprotein antibody | D component of complement antibody
Specifications & PurityCarrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host speciesHuman
SpecificityCFD
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionAntibody of complement factor D
Product Description

Lampalizumab (anti-Complement Factor D) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab (anti-Complement Factor D) binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab (anti-Complement Factor D) can be used for age-related macular degeneration (AMD) research.

Product Properties

IsotypeHuman IgG1
Light Chain Typekappa
SDS-PAGE25.7 kDa (Light Chain) & 50.8 kDa (Heavy Chain), under reducing conditions; 180.0 kDa, under non-reducing conditions.
Purification MethodProtein A purified
Purity>95%
FormLiquid
ConcentrationSee COA
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1278466-20-8

Images

Lampalizumab (anti-Complement Factor D) (Ab175571) - SEC
The purity of Lampalizumab (anti-Complement Factor D) (Ab175571) is more than 95% verified by HPLC.

Associated Targets(Human)

CFD Tchem Complement factor D (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences
Complement factor D inhibitorINHIBITORALA2176771Complement factor DSINGLE PROTEINHomo sapiens

PubMed: [1] , [2]


Complement factor D inhibitorINHIBITORALA2176771Complement factor DSINGLE PROTEINHomo sapiens

Other: [1]


PubMed: [1]


Certificates

C of A & Other Certificates(BSE/TSE, COO)

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0405069Certificate of AnalysisApr 30, 2024 Ab175571
ZJ24F0405068Certificate of AnalysisApr 30, 2024 Ab175571
ZJ24F0405067Certificate of AnalysisApr 30, 2024 Ab175571

Related Documents

References

1. Tanhehco EJ, Kilgore KS, Liff DA, Murphy KL, Fung MS, Sun WN, Sun C, Lucchesi BR.  (1999)  The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system..  Transplant Proc,  31  (5): (2168-71).  [PMID:10456004] [10.1021/op500134e]
2. Fung M, Loubser PG, Undar A, Mueller M, Sun C, Sun WN, Vaughn WK, Fraser Jr CD.  (2001)  Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits..  J Thorac Cardiovasc Surg,  122  (1): (113-22).  [PMID:11436043] [10.1021/op500134e]
3. Charbel Issa P, Chong NV, Scholl HP.  (2011)  The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application..  Graefes Arch Clin Exp Ophthalmol,  249  (2): (163-74).  [PMID:21127893] [10.1021/op500134e]
4. Do DV, Pieramici DJ, van Lookeren Campagne M, Beres T, Friesenhahn M, Zhang Y, Strauss EC, Phase Ia Investigators.  (2014)  A phase ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy..  Retina (Philadelphia, PA),  34  (2): (313-20).  [PMID:23842100] [10.1021/op500134e]
5. Yang CY, Phillips JG, Stuckey JA, Bai L, Sun H, Delproposto J, Brown WC, Chinnaswamy K..  (2016)  Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors..  ACS Med Chem Lett,  (12): (1092-1096).  [PMID:27994744] [10.1021/acsmedchemlett.6b00299]
6. Vulpetti A, Randl S, Rüdisser S, Ostermann N, Erbel P, Mac Sweeney A, Zoller T, Salem B, Gerhartz B, Cumin F, Hommel U, Dalvit C, Lorthiois E, Maibaum J..  (2017)  Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors..  J Med Chem,  60  (5): (1946-1958).  [PMID:28157311] [10.1021/acs.jmedchem.6b01684]
7. Velcicky J,Wilcken R,Cotesta S,Janser P,Schlapbach A,Wagner T,Piechon P,Villard F,Bouhelal R,Piller F,Harlfinger S,Stringer R,Fehlmann D,Kaupmann K,Littlewood-Evans A,Haffke M,Gommermann N.  (2020)  Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure..  J Med Chem,  63  (17): (9856-9875).  [PMID:32856916] [10.1021/acs.jmedchem.0c01020]
8. White, R T RT and 7 more authors..  (1992)  Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue..  The Journal of biological chemistry,    (5):   [PMID:1374388]
9. Johnson, D M DM, Gagnon, J J and Reid, K B KB..  (1984)  Amino acid sequence of human factor D of the complement system. Similarity in sequence between factor D and proteases of non-plasma origin..  FEBS letters,    (30):   [PMID:6363133]
10. Niemann, M A MA, Bhown, A S AS, Bennett, J C JC and Volanakis, J E JE..  (1984)  Amino acid sequence of human D of the alternative complement pathway..  Biochemistry,    (22):   [PMID:6383466]
11. and Davis, A E AE..  (1980)  Active site amino acid sequence of human factor D..  Proceedings of the National Academy of Sciences of the United States of America,      [PMID:6776531]
12. Johnson, D M DM, Gagnon, J J and Reid, K B KB..  (1980)  Factor D of the alternative pathway of human complement. Purification, alignment and N-terminal amino acid sequences of the major cyanogen bromide fragments, and localization of the serine residue at the active site..  The Biochemical journal,    (1):   [PMID:6821372]
13. Volanakis, J E JE, Bhown, A A, Bennett, J C JC and Mole, J E JE..  (1980)  Partial amino acid sequence of human factor D:homology with serine proteases..  Proceedings of the National Academy of Sciences of the United States of America,      [PMID:6987665]
14. Kim, S S, Narayana, S V SV and Volanakis, J E JE..  (1995)  Crystal structure of a complement factor D mutant expressing enhanced catalytic activity..  The Journal of biological chemistry,    (13):   [PMID:7592653]
15. Narayana, S V SV and 8 more authors..  (1994)  Structure of human factor D. A complement system protein at 2.0 A resolution..  Journal of molecular biology,    (14):   [PMID:8289289]
16. Sprong, Tom T and 6 more authors..  (2006)  Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections..  Blood,    (15):   [PMID:16527897]
17. Maibaum, Jürgen J and 28 more authors..  (2016)  Small-molecule factor D inhibitors targeting the alternative complement pathway..  Nature chemical biology,      [PMID:27775713]

Solution Calculators